Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Sorafenib in Patients With Advanced Anaplastic Thyroid Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Active	18 and over	NCI	CASE-5304 CASE 5304, 7037, NCI-7037, NCT00126568

Trial Description

Purpose:

Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Measurable or evaluable disease
• No brain metastases
• No more than two previous chemotherapy regimens
• No previous sorafenib
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive sorafenib by mouth twice a day. Treatment may continue for as long as benefit is shown.

Patients will be evaluated periodically.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Case Comprehensive Cancer Center

Panos Savvides, MD, Protocol chair		Ph: 216-844-5946

U.S.A.
Michigan
	Detroit
	Josephine Ford Cancer Center at Henry Ford Hospital
		Contact Person	Ph:  313-916-1850 888-734-5322
Ohio
	Cleveland
	Case Comprehensive Cancer Center
		Clinical Trials Office - Case Comprehensive Cancer Center	Ph:  800-641-2422
	Geauga Regional Hospital
		Scot Remick	Ph:  216-844-5176
	Lake/University Ireland Cancer Center
		Scot Remick	Ph:  216-844-5176
	Mercy Cancer Center at Mercy Medical Center
		Scot Remick	Ph:  216-844-5176
	Southwest General Health Center
		Scot Remick	Ph:  216-844-5176
	UHHS Chagrin Highlands Medical Center
		Scot Remick	Ph:  216-844-5176
	UHHS Westlake Medical Center
		Scot Remick	Ph:  216-844-5176
	University Suburban Health Center
		Scot Remick	Ph:  216-844-5176

Registry Information
Official Title		Phase II Trial of BAY 43-9006 in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Trial Start Date		2005-06-14
Trial Completion Date		2006-12-06 (estimated)
Registered in ClinicalTrials.gov		NCT00126568
Date Submitted to PDQ		2005-06-15
Information Last Verified		2009-04-29
NCI Grant/Contract Number		CA43703, CA62502